High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment

被引:65
|
作者
Naik, Biswajit [1 ]
Gupta, Nidhi [1 ]
Ojha, Rupal [1 ]
Singh, Satyendra [1 ]
Prajapati, Vijay Kumar [1 ]
Prusty, Dhaneswar [1 ]
机构
[1] Cent Univ Rajasthan, Sch Life Sci, Dept Biochem, NH-8, Ajmer 305817, Rajasthan, India
关键词
COVID-19; Natural compounds; Muti-target; Molecular docking; Molecular dynamics; MOLECULAR DOCKING; SARS CORONAVIRUS; STRUCTURE VALIDATION; ANTIOXIDANT ACTIVITY; POTENT INHIBITORS; CRYSTAL-STRUCTURE; VIRUS ACTIVITY; DRUG TARGETS; EBOLA-VIRUS; RNA VIRUS;
D O I
10.1016/j.ijbiomac.2020.05.184
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The present-day world is severely suffering from the recently emerged SARS-CoV-2. The lack of prescribed drugs for the deadly virus has stressed the likely need to identify novel inhibitors to alleviate and stop the pandemic. In the present high throughput virtual screening study, we used in silico techniques like receptor-ligand docking, Molecular dynamic (MD), and ADME properties to screen natural compounds. It has been documented that many natural compounds display antiviral activities, including anti-SARS-CoV effect. The present study deals with compounds of Natural Product Activity and Species Source (NPASS) database with known biological activity that probably impedes the activity of six essential enzymes of the virus. Promising drug-like compounds were identified, demonstrating better docking score and binding energy for each druggable targets. After an extensive screening analysis, three novel multi-target natural compounds were predicted to subdue the activity of three/more major drug targets simultaneously. Concerning the utility of natural compounds in the formulation of many therapies, we propose these compounds as excellent lead candidates for the development of therapeutic drugs against SARS-CoV-2. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 17
页数:17
相关论文
共 50 条
  • [41] Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
    Jia, Zaixing
    Gong, Wenping
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2021, 36 (18)
  • [42] SARS-CoV-2 Spike Proteins: A Key Target for COVID-19 Therapeutics Development
    Kohli, Khushi
    Liu, Samuel
    Garapaty, Arjun
    FASEB JOURNAL, 2021, 35
  • [43] Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19
    Cao, Junyuan
    Liu, Yang
    Zhou, Minmin
    Dong, Siqi
    Hou, Yuxia
    Jia, Xiaoying
    Lan, Xiaohao
    Zhang, Yueli
    Guo, Jiao
    Xiao, Gengfu
    Wang, Wei
    VIRUSES-BASEL, 2022, 14 (02):
  • [44] Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19
    Marinella, Mark A.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2020, 74 (09)
  • [45] SARS-CoV-2 (COVID-19) Protection Efforts on Acute Stroke Treatment
    Greenwood, Jessica
    Belnap, Starlie
    Bedgio, Rodney
    Dabus, Guilherme
    Linfante, Italo
    De Los Rios La Rosa, Felipe
    STROKE, 2021, 52
  • [46] Early Outpatient Treatment of SARS-CoV-2 (COVID-19): A Comment Reply
    McCullough, Peter A.
    AMERICAN JOURNAL OF MEDICINE, 2021, 134 (03): : E222 - E223
  • [47] Preoperative SARS-CoV-2 screening: Can it really rule out COVID-19?
    Lother, Sylvain A.
    CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 2020, 67 (10): : 1321 - 1326
  • [48] Systematic SARS-CoV-2 screening in cerebrospinal fluid during the COVID-19 pandemic
    Destras, Gregory
    Bal, Antonin
    Escuret, Vanessa
    Morfin, Florence
    Lina, Bruno
    Josset, Laurence
    LANCET MICROBE, 2020, 1 (04): : E149 - E149
  • [49] Screening the General Population for SARS-CoV-2 Virus and COVID-19 Antibodies: A Counterargument
    Wu, Alan H. B.
    JOURNAL OF APPLIED LABORATORY MEDICINE, 2020, 5 (05): : 1107 - 1110
  • [50] An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
    Drozdzal, Sylwester
    Rosik, Jakub
    Lechowicz, Kacper
    Machaj, Filip
    Szostak, Bartosz
    Przybycinski, Jaroslaw
    Lorzadeh, Shahrokh
    Kotfis, Katarzyna
    Ghavami, Saeid
    Los, Marek J.
    DRUG RESISTANCE UPDATES, 2021, 59